免疫相关不良反应发生机制的研究进展

杨 洵, 侯丽 君*
山东第一医科大学第二附属医院内分泌科

摘要


ICIs通过阻断PD-1、PD-L1和CTLA-4通路增强抗肿瘤免疫反应，但同时也引发irAEs。本文系统综述了
ICIs相关irAEs的流行病学特征及病理生理机制，主要涉及T细胞过度激活、交叉反应性抗原识别及肠道微生物组调
节失衡。未来研究方向包括预测模型开发及管理策略的优化。

关键词


免疫检查点抑制剂；免疫相关不良反应；病理生理机制；多器官毒性；预测生物标志物

全文:

PDF


参考


[1]Jayson A, Tsambarlis M, Thakkar H, et al.

Multisystem immune-related adverse reactions with immune

checkpoint inhibitors[J]. Jaapa, 2025, 38(6): 29-31.

[2]Li N, Wang G, Hou X, et al. Adverse and

unconventional reactions related to immune checkpoint inhibitor

therapy for cancer[J]. International Immunopharmacology, 2022,

108: 108803.

[3]Chera A, Stancu A L, Bucur O. Thyroid-related

adverse events induced by immune checkpoint inhibitors[J].

Frontiers in endocrinology, 2022, 13: 1010279.

[4]Muhaj F, Karri P V, Moody W, et al. Mucocutaneous

adverse events to immune checkpoint inhibitors[J]. Frontiers

in Allergy, 2023, 4: 1147513.

[5]Luo L, Lin C, Wang P, et al. Combined use of immune

checkpoint inhibitors and phytochemicals as a novel therapeutic

strategy against cancer[J]. Journal of Cancer, 2023, 14(12): 2315-

2328.

[6]Jungles K M, Holcomb E A, Pearson A N, et al.

Updates in combined approaches of radiotherapy and immune

checkpoint inhibitors for the treatment of breast cancer[J].

Frontiers in Oncology, 2022, 12: 1022542.

[7]Kaushik I, Ramachandran S, Zabel C, et al. The

evolutionary legacy of immune checkpoint inhibitors[J].

Seminars in Cancer Biology, 2022, 86: 491-498.

[8]Xiong H, Shen Z. Tissue-resident memory T cells

in immunotherapy and immune-related adverse events by

immune checkpoint inhibitor[J]. International Journal of

Cancer, 2024, 155(2): 193-202.

[9]Singh S, Clemente L C, Parra E R, et al. Urinary

T cells are detected in patients with immune checkpoint

inhibitor-associated immune nephritis that are clonotypically

identical to kidney T cell infiltrates[J]. OncoImmunology,

2022, 11(1): 2124678.

[10]Attias M, Piccirillo C A. The impact of Foxp3+

regulatory T-cells on CD8+ T-cell dysfunction in tumour

microenvironments and responses to immune checkpoint

inhibitors[J]. British Journal of Pharmacology, 2026, 183(6):

1250-1270.

[11]Li H, Zhao A, Li M, et al. Targeting T-cell

metabolism to boost immune checkpoint inhibitor therapy[J].

Frontiers in Immunology, 2022, 13: 1046755.

[12]Zhou G, Zhang N, Meng K, et al. Interaction

between gut microbiota and immune checkpoint inhibitorrelated colitis[J]. Frontiers in Immunology, 2022, 13: 1001623.

[13]Zhao H, Wang D, Zhang Z, et al. Effect of gut

microbiota-derived metabolites on immune checkpoint

inhibitor therapy: enemy or friend?[J]. Molecules, 2022,

27(15): 4799.

[14]Zhang H, Hong Y, Wu T, et al. Role of gut

microbiota in regulating immune checkpoint inhibitor therapy

for glioblastoma[J]. Frontiers in Immunology, 2024, 15: 1401967.


Refbacks

  • 当前没有refback。